CLINICAL_TRIALS
research
· 2026-04-03
Clinical Trial Update: Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD) [Phase 3]
Summary
A Phase 3 clinical trial evaluating subcutaneous VGA039 in patients with Von Willebrand disease is currently recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Vega Therapeutics, Inc | Conditions: Von Willebrand Disease (VWD) | Phase 3 | Status: RECRUITING